Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 June 2023 | Story Dr Nokuthula Tlalajoe-Mokhatla | Photo Supplied
Dr Nokuthula Tlalajoe-Mokhatla
Dr Nokuthula Tlalajoe-Mokhatla, Academic Head and Senior Lecturer at the Division of Student Learning and Development.

The University of the Free State (UFS) is celebrating Youth Month by showcasing the positive influence of the institution on career development. As part of this initiative, we are sharing the stories of UFS alumni who are now working at the university.

Dr Nokuthula Tlalajoe-Mokhatla, Academic Head and Senior Lecturer at the Division of Student Learning and Development, shares her UFS journey:

Q: Year of graduation from the UFS:

A: I graduated in 2010, 2011, 2013, and 2021 (virtual graduation).

Q: Qualification obtained from the UFS:
A: BSc Biochemistry and Microbiology, BSc Honours Biochemistry, MSc Biochemistry (Cum Laude), PhD in Health Professions Education

Q: Date of joining the UFS as a staff member:
A: I joined as an official staff member on 18 January 2016; however, I have been in the HR system since my third year (2009) when I was appointed as a Laboratory Assistant.

Q: Initial job title and current job title:

A: In the context of point 3, I would safely say I moved from Laboratory Assistant, to Demonstrator, to Lecturer, and now Academic Head of the division and Senior Lecturer.

Q: How did the UFS prepare you for the professional world?

A: Every human being can be taught a skill, be it a scientist, health professional, or accountant. However, how their soft skills complement or lack to complement the core knowledge and application will set that individual apart. That being said, I have utilised the vast opportunities that are always accessible to enhance one's development with regard to lifelong learning skills. My biggest gain was the Engaged Leadership Programme (middle management level), which I completed in 32 weeks and obtained a distinction. That type of training set me in a position that could easily have played a role in me being able to progress further in the professional world.

Q: What are your thoughts on transitioning from a UFS alumnus to a staff member?

A: The outlook is so different when you are a staff member. I am enjoying the world of being a staff member more. This is due to my struggles as a student – a story for another day. The perks and benefits are more as a staff member, and your world gets bigger and bigger. Networking with like-minded people and contributing to day-to-day activities is mind-blowing for me.

Q: Any additional comments about your experience?
A: I appreciate the support systems in our setting; it comes in handy when we doubt ourselves and think we are not enough or adequate. What I do appreciate is the opportunities that are accessible, and with the help we have in place, it brings a sense of ease to know you can equally access it.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept